Clinical Commander

Back to dossier
cardio.stemi.transplant-recipient.v1PRODUCTION
cardio.stemi.transplant-recipient.v1

STEMI in cardiac transplant recipient (CAV-driven)

cardiologyacuteadult
Hard-required inputs
0 / 10
Care setting:

Encounter flow

12/12 authored

Canonical 12-phase frame with authored status for this dossier.

Current phase

Frame

Detailed

Cardiac transplant recipient with ST elevation — differential dominated by CAV-driven STEMI; concurrent rejection (ACR/AMR) possible; classical plaque rupture less common; inherits STEMI arc from cardio.stemi.core.v1

Inputs
2
Actions
0
Advance rule
Set
Advance when

Transplant context + CAV vs rejection vs plaque-rupture framed

Patient inputs (13)

Recipient age + transplant vintage shape CAV burden vs concurrent rejection probability

Time post-transplant: <1 yr → ACR/AMR more likely co-driver; >5 yr → CAV dominates (ISHLT 2023)

Tacrolimus / cyclosporine (CNI) trough levels + MMF + prednisone regimen drives differential and adjustment plan; CYP3A4 interactions with statins, CCB, antibiotics

CNI nephrotoxicity baseline; informs imaging contrast safety + AC dosing; AVOID NSAIDs absolutely

Sub-therapeutic CNI trough → concurrent rejection risk; supratherapeutic → toxicity (KDIGO transplant 2009)

Graft injury marker; persistent rise + ST elevation = STEMI-equivalent; persistent rise without ST changes → rejection workup

Diagnostic + monitoring; rises with STEMI, CAV-driven dysfunction, and concurrent rejection

STAT echo for new LV/RV dysfunction; restrictive pattern can suggest concurrent rejection; baseline LVEF comparison critical

Hypotension + STEMI in transplant recipient → cardiogenic-shock pathway; CNI-related vasoplegia possible

Coronary angiography typically shows diffuse pruning + small-vessel disease + epicardial stenosis (CAV signature); IVUS gold standard for CAV detection (intimal thickness >0.5 mm) per ISHLT staging

Donor-specific antibodies — required if concurrent AMR suspected (ISHLT 2013 AMR criteria)

Gadolinium-enhanced cardiac MRI for CAV burden + scar + ischemia (avoid if eGFR <30)

Gold standard for ACR (ISHLT 2010) and AMR (pAMR0–pAMR3) — perform if concurrent rejection suspected (sub-therapeutic CNI, DSA positivity, restrictive echo pattern)

* = hard-required. Engine cannot meaningfully run until these are filled.

Severity triggers (5)

5 need judgement
  • informationallife_threateningdiffuse_cav_pattern_not_pci_amenable
    Coronary angiography + IVUS reveal diffuse small-vessel CAV without focal lesion suitable for PCI — medical management + re-transplant evaluation indicated
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationallife_threateningre_transplant_decision_for_severe_cav_with_stemi
    STEMI in transplant recipient with biopsy-confirmed CAV ISHLT 3 + LVEF <30 + non-recoverable graft — re-transplant listing decision
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationallife_threateningconcurrent_amr_with_stemi
    Endomyocardial biopsy pAMR2 or pAMR3 + DSA positive in transplant recipient with STEMI — compounded ischemia + rejection requires multimodal therapy
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalseverensaid_exposure_with_aki_in_transplant_recipient
    Inadvertent NSAID administration to transplant recipient + creatinine rise — allograft nephrotoxicity + CNI synergistic AKI
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalseverecyp3a4_drug_interaction_cyclosporine_or_tacrolimus_with_statin
    Inadvertent administration of CYP3A4-metabolised statin (simvastatin / lovastatin) to transplant recipient on CNI — risk of toxic statin levels and rhabdomyolysis
    Trigger could not be auto-evaluated — needs clinician judgement.

Workflow calculators

Run this disease's risk and dosing calculators inline.

RISK_STRATIFICATIONrequiredDrives risk stratification
Loading…

Recommended regimen

STEMI in cardiac transplant recipient — CAV-aware ACS bundle; CYP3A4-safe statin selection; AVOID NSAIDs absolutely; cautious CCB (CNI interactions); mTOR substitution for long-term CAV progression
axis: transplant_stemi_phenotype
Selected axis "STEMI in cardiac transplant recipient — CAV-aware ACS bundle; CYP3A4-safe statin selection; AVOID NSAIDs absolutely; cautious CCB (CNI interactions); mTOR substitution for long-term CAV progression" by default fallback (first axis)
  • aspirin
    first line
    antiplatelet_cox1
    162–325 mg load → 81 mg • PO chewed • load once → 81 mg daily
    triggers: transplant_stemi_confirmed
    Universal STEMI — ACC/AHA 2025 Class I; same as parent cardio.stemi.core.v1; no CNI interaction
    rxcui 243670
  • ticagrelor
    first line
    p2y12_inhibitor
    180 mg load → 90 mg BID • PO • BID × 12 mo
    triggers: transplant_stemi_pci_planned
    PLATO PMID 19717846; ACC/AHA 2025 Class I; minor CYP3A4 interaction with CNI but tolerated; clopidogrel acceptable alternative if drug-drug concerns
    rxcui 1116632
  • unfractionated heparin
    first line
    parenteral_anticoagulant
    70–100 U/kg bolus → infusion to ACT 250–300 during PCI • IV • continuous, ACT-guided
    triggers: transplant_stemi_pci_planned
    ACC/AHA 2025 Class I parenteral AC; reversible; renal-friendly; preferred over enoxaparin in transplant given CNI nephrotoxicity baseline
    rxcui 5224
  • pravastatin
    first line
    statin_low_intensity_cyp3a4_safe
    40–80 mg • PO • daily
    triggers: transplant_stemi_confirmed, cni_concomitant
    ISHLT 2023 Class I + Kobashigawa NEJM 1995 PMID 7637810 — pravastatin is CYP3A4-neutral so does not interact with calcineurin inhibitors; standard transplant statin; AVOID simvastatin/lovastatin (CYP3A4 metabolised)
    rxcui 42463
  • pitavastatin
    add on
    statin_high_intensity_cyp3a4_safe
    2–4 mg • PO • daily
    triggers: transplant_stemi_confirmed, ldl_above_target_on_pravastatin
    CYP-neutral high-intensity statin alternative; ISHLT 2023 acceptable; consider if pravastatin insufficient for LDL target <70 (or <55 very-high-risk)
    rxcui 861634
  • methylprednisolone
    comorbidity specific
    corticosteroid
    1000 mg IV daily × 3 d (pulse therapy) • IV • daily × 3
    triggers: concurrent_acr_grade_2r_or_higher, concurrent_amr_with_lv_dysfunction
    ISHLT 2010 (Stewart PMID 21177015) — pulse steroids first line for ≥2R ACR; also adjunct in AMR; for STEMI patients with concurrent rejection on biopsy
    rxcui 6902
  • tacrolimus
    first line
    calcineurin_inhibitor
    Maintain trough 5–10 ng/mL late post-transplant; AVOID over-reduction • PO • BID
    triggers: transplant_maintenance, sub_therapeutic_trough_with_concurrent_rejection
    KDIGO transplant 2009 — narrow therapeutic window; sub-therapeutic trough is a modifiable rejection driver and may compound CAV-driven STEMI substrate
    rxcui 42316
  • sirolimus
    comorbidity specific
    mtor_inhibitor
    Trough 4–8 ng/mL with CNI reduction • PO • daily
    triggers: cav_progression_post_stemi, cav_ishlt_2_3_with_acceptable_renal_function
    CAVS-1 / CRAD trial — mTOR inhibitor switch (with CNI reduction) slows CAV progression; consider after STEMI in transplant recipient with confirmed CAV substrate; NOT acute therapy
    rxcui 35302
  • carvedilol
    add on
    mixed_alpha_beta_blocker
    3.125 mg BID titrate • PO • BID
    triggers: post_stemi_ef_lt_40_in_transplant_recipient, documented_chronic_HF_in_graft
    Standard post-MI BB per ACC/AHA 2025; denervated graft adrenergic response uncertain but BB still reasonable for HFrEF; CAPRICORN PMID 11356436 historical context
    rxcui 20352

outpatient playbook — drug actions (4)

  1. 1. continue DAPT through 12 mo then ASA monotherapy
    rxcui 321208
    aspirin 81 + ticagrelor 90 BID × 12 mo, then ASA 81 alone • PO • as scheduled
    trigger: Post-cath maintenance
    PARIS adherence-vs-stent-thrombosis; PLATO PMID 19717846
  2. 2. continue triple immunosuppression long-term
    rxcui 42316
    tacrolimus trough 5–8 ng/mL late + MMF 1000 BID + prednisone 2.5–5 daily • PO • as scheduled
    trigger: transplant maintenance
    ISHLT 2023; lower troughs late to balance CAV/malignancy/infection vs rejection risk
  3. 3. pravastatin or pitavastatin maintenance
    rxcui 617314
    pravastatin 40–80 mg or pitavastatin 2–4 mg • PO • daily
    trigger: transplant maintenance — CAV prevention
    ISHLT 2023 Class I; Kobashigawa NEJM 1995 PMID 7637810; LDL target <70 (or <55 very-high-risk)
  4. 4. consider mTOR switch (sirolimus/everolimus) for CAV progression
    rxcui 35302
    sirolimus per trough 4–8 ng/mL; reduce CNI • PO • daily
    trigger: CAV progression on annual angio
    CAVS-1 / CRAD — mTOR slows CAV progression

Auto-drafted A&P note

outpatient

Subjective

- Possible entry pathways: New ST elevation ≥1 mm in ≥2 contiguous leads on ECG in cardiac transplant recipient; Unexplained troponin rise + new LVEF reduction on echo in transplant recipient (STEMI-equivalent in denervated graft); Transplant recipient (denervated graft) with new dyspnea / hemodynamic deterioration + ST changes — silent ischemia pattern (no classic angina).

Objective

- No vitals, labs, or imaging entered for this encounter.

Assessment

**STEMI in cardiac transplant recipient (CAV-driven)** (cardio.stemi.transplant-recipient.v1).
Phenotype framing: CAV-driven STEMI (diffuse) vs CAV focal lesion (PCI-amenable) vs classical plaque-rupture STEMI vs concurrent ACR/AMR vs CMV myocarditis vs Takotsubo per ISHLT 2023 + 4th UDMI 2018
Scope: Cardiac transplant recipient with ST elevation — differential dominated by CAV-driven STEMI; concurrent rejection (ACR/AMR) possible; classical plaque rupture less common; inherits STEMI arc from cardio.stemi.core.v1

No severity triggers fired against current inputs.

Plan

Regimen axis: **STEMI in cardiac transplant recipient — CAV-aware ACS bundle; CYP3A4-safe statin selection; AVOID NSAIDs absolutely; cautious CCB (CNI interactions); mTOR substitution for long-term CAV progression**.
1. aspirin 162–325 mg load → 81 mg PO chewed load once → 81 mg daily (antiplatelet_cox1, first line) — Universal STEMI — ACC/AHA 2025 Class I; same as parent cardio.stemi.core.v1; no CNI interaction
2. ticagrelor 180 mg load → 90 mg BID PO BID × 12 mo (p2y12_inhibitor, first line) — PLATO PMID 19717846; ACC/AHA 2025 Class I; minor CYP3A4 interaction with CNI but tolerated; clopidogrel acceptable alternative if drug-drug concerns
3. unfractionated heparin 70–100 U/kg bolus → infusion to ACT 250–300 during PCI IV continuous, ACT-guided (parenteral_anticoagulant, first line) — ACC/AHA 2025 Class I parenteral AC; reversible; renal-friendly; preferred over enoxaparin in transplant given CNI nephrotoxicity baseline
4. pravastatin 40–80 mg PO daily (statin_low_intensity_cyp3a4_safe, first line) — ISHLT 2023 Class I + Kobashigawa NEJM 1995 PMID 7637810 — pravastatin is CYP3A4-neutral so does not interact with calcineurin inhibitors; standard transplant statin; AVOID simvastatin/lovastatin (CYP3A4 metabolised)
5. pitavastatin 2–4 mg PO daily (statin_high_intensity_cyp3a4_safe, add on) — CYP-neutral high-intensity statin alternative; ISHLT 2023 acceptable; consider if pravastatin insufficient for LDL target <70 (or <55 very-high-risk)
6. methylprednisolone 1000 mg IV daily × 3 d (pulse therapy) IV daily × 3 (corticosteroid, comorbidity specific) — ISHLT 2010 (Stewart PMID 21177015) — pulse steroids first line for ≥2R ACR; also adjunct in AMR; for STEMI patients with concurrent rejection on biopsy
7. tacrolimus Maintain trough 5–10 ng/mL late post-transplant; AVOID over-reduction PO BID (calcineurin_inhibitor, first line) — KDIGO transplant 2009 — narrow therapeutic window; sub-therapeutic trough is a modifiable rejection driver and may compound CAV-driven STEMI substrate
8. sirolimus Trough 4–8 ng/mL with CNI reduction PO daily (mtor_inhibitor, comorbidity specific) — CAVS-1 / CRAD trial — mTOR inhibitor switch (with CNI reduction) slows CAV progression; consider after STEMI in transplant recipient with confirmed CAV substrate; NOT acute therapy
9. carvedilol 3.125 mg BID titrate PO BID (mixed_alpha_beta_blocker, add on) — Standard post-MI BB per ACC/AHA 2025; denervated graft adrenergic response uncertain but BB still reasonable for HFrEF; CAPRICORN PMID 11356436 historical context

Setting playbook (outpatient) — Long-term transplant cardiology surveillance: annual coronary angiography or IVUS for CAV progression, surveillance biopsy schedule, DSA monitoring, CYP3A4-safe statin maintenance, mTOR substitution for CAV slowing, re-transplant listing decisions
10. continue DAPT through 12 mo then ASA monotherapy aspirin 81 + ticagrelor 90 BID × 12 mo, then ASA 81 alone PO as scheduled — Post-cath maintenance (PARIS adherence-vs-stent-thrombosis; PLATO PMID 19717846)
11. continue triple immunosuppression long-term tacrolimus trough 5–8 ng/mL late + MMF 1000 BID + prednisone 2.5–5 daily PO as scheduled — transplant maintenance (ISHLT 2023; lower troughs late to balance CAV/malignancy/infection vs rejection risk)
12. pravastatin or pitavastatin maintenance pravastatin 40–80 mg or pitavastatin 2–4 mg PO daily — transplant maintenance — CAV prevention (ISHLT 2023 Class I; Kobashigawa NEJM 1995 PMID 7637810; LDL target <70 (or <55 very-high-risk))
13. consider mTOR switch (sirolimus/everolimus) for CAV progression sirolimus per trough 4–8 ng/mL; reduce CNI PO daily — CAV progression on annual angio (CAVS-1 / CRAD — mTOR slows CAV progression)

Non-pharmacologic actions:
- Annual CAV imaging
- Sun protection + dermatology yearly
- Vaccinations (no live)
- Adherence reinforcement
- Cardiac rehab maintenance phase (modified intensity)

AVOID / contraindication checks:
- Nsaid_avoid_absolutely (allograft nephrotoxicity; CNI synergistic AKI)
- Simvastatin_lovastatin_avoid_with_cni (CYP3A4 — toxic statin levels and rhabdo)
- Diltiazem_verapamil_avoid_with_cni (CYP3A4 — toxic CNI levels; if BP control needed, prefer amlodipine with close CNI monitoring)
- Clarithromycin_azole_antifungal_avoid_with_cni (CYP3A4 — toxic CNI levels)
- Cni_minimal_reduction_only (over reduction precipitates rejection — narrow therapeutic window)
- Live_vaccines_contraindicated (chronic immunosuppression)
- Gadolinium_avoid_if_egfr_below_30 (NSF risk; defer cardiac MRI)

Monitoring

Regimen monitoring:
- CNI trough daily during acute STEMI period
- Troponin q6h × 24 h post-PCI
- Surveillance biopsy at 2 wk if concurrent rejection suspected
- DSA titer q month × 3 if AMR co-driver
- Echo at 5–7 d for LV thrombus + LV recovery
- Annual CAV imaging (angio + IVUS) post-event
- Hgb q12 h on triple antithrombotic (BARC 2011)
- Creatinine q24 h on AC + post-contrast (KDIGO 2026)

Setting (outpatient) monitoring:
- Quarterly clinic + labs
- Annual CAV imaging + DSA + cancer screen
- Lipid panel q 6 mo

Follow-up plan: Transplant cardiology long-term: annual angio/IVUS for CAV; surveillance biopsy per program; mTOR inhibitor (sirolimus / everolimus) substitution for CNI to slow CAV progression per CAVS-1 / CRAD; statin maintenance (CYP3A4-safe); cardiac rehab; re-transplant listing if CAV ISHLT 3 with non-recoverable graft
- Close-out criterion: Transplant program plan + mTOR consideration documented

Monitoring phase: Repeat troponin q6h × 24 h; CNI troughs daily; surveillance biopsy at 2 wk if any rejection suspicion; DSA q month × 3; echo at 5–7 d for thrombus + LV recovery; annual CAV imaging

Disposition

Current setting: outpatient — Long-term transplant cardiology surveillance: annual coronary angiography or IVUS for CAV progression, surveillance biopsy schedule, DSA monitoring, CYP3A4-safe statin maintenance, mTOR substitution for CAV slowing, re-transplant listing decisions

Disposition criteria:
- Long-term continuation with transplant program; cross-link to cardio.acute-hf.transplant-recipient.v1 for residual HFrEF management

Escalation triggers (move to higher acuity):
- New LV dysfunction → STAT biopsy + DSA + cath
- CAV ISHLT 3 progression → re-transplant evaluation
- PTLD suspicion → reduce immunosuppression + oncology consult
- Recurrent ischemic event → urgent re-cath

Earlier-Return Triggers

Return-precaution thresholds (watch for):
- [LIFE_THREATENING] Coronary angiography + IVUS reveal diffuse small-vessel CAV without focal lesion suitable for PCI — medical management + re-transplant evaluation indicated
- [LIFE_THREATENING] STEMI in transplant recipient with biopsy-confirmed CAV ISHLT 3 + LVEF <30 + non-recoverable graft — re-transplant listing decision
- [LIFE_THREATENING] Endomyocardial biopsy pAMR2 or pAMR3 + DSA positive in transplant recipient with STEMI — compounded ischemia + rejection requires multimodal therapy

Citations

- ISHLT 2010 ACR grading + ISHLT 2013 AMR working formulation + ISHLT 2023 update + 2025 ACC/AHA ACS Guideline (Rao) + KDIGO transplant 2009 [PMID:21177015](https://pubmed.ncbi.nlm.nih.gov/21177015/)
- Cited evidence (PMID 23446352) [PMID:23446352](https://pubmed.ncbi.nlm.nih.gov/23446352/)
- Cited evidence (PMID 25997674) [PMID:25997674](https://pubmed.ncbi.nlm.nih.gov/25997674/)
- Cited evidence (PMID 26277690) [PMID:26277690](https://pubmed.ncbi.nlm.nih.gov/26277690/)
- Cited evidence (PMID 32067844) [PMID:32067844](https://pubmed.ncbi.nlm.nih.gov/32067844/)

Last reconciled with current guidelines: 2026-05-15.
References
  • ISHLT 2010 ACR grading + ISHLT 2013 AMR working formulation + ISHLT 2023 update + 2025 ACC/AHA ACS Guideline (Rao) + KDIGO transplant 2009 — PMID:21177015
  • Cited evidence (PMID 23446352) — PMID:23446352
  • Cited evidence (PMID 25997674) — PMID:25997674
  • Cited evidence (PMID 26277690) — PMID:26277690
  • Cited evidence (PMID 32067844) — PMID:32067844